Ambassadeur de la Health Valley, Glenmark signe un accord de licence avec le sud-coréen Yuhan Corporation

Ambassadeur de la Health Valley, Glenmark signe un accord de licence avec le sud-coréen Yuhan Corporation

Glenmark Pharmaceuticals’ Suisse subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Yuhan Corporation for commercializing its novel nasal spray Ryaltris in South Korea.

Ryaltris olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg), developed by Glenmark, is a novel, investigational, fixed‐dose combination nasal spray of an anti‐histamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.

MORE

Leave a reply